Compare Stocks: ALGS, OTLK, AVXL, and ALXO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.23 -5.1%	$5.97	$3.98 ▼ $13.69	$32.64M	2.36	139,044 shs	60,554 shs
ALXO ALX Oncology	$0.89 -8.7%	$1.74	$0.89 ▼ $2.66	$123.72M	0.47	1.06 million shs	2.57 million shs
AVXL Anavex Life Sciences	$1.49 +0.7%	$2.64	$1.44 ▼ $9.50	$138.12M	1.17	1.25 million shs	1.23 million shs
OTLK Oncobiologics	$0.47 -16.6%	$0.68	$0.16 ▼ $2.54	$114.47M	0.66	12.16 million shs	9.56 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-0.36%	+2.42%	+5.56%	-4.51%	-41.82%
ALXO ALX Oncology	-22.25%	-11.75%	-49.51%	-51.74%	-47.05%
AVXL Anavex Life Sciences	-1.99%	-7.50%	-43.51%	-40.80%	-82.83%
OTLK Oncobiologics	-4.44%	-1.43%	-14.58%	-63.86%	-56.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$5.23 -5.1%	$5.97	$3.98 ▼ $13.69	$32.64M	2.36	139,044 shs	60,554 shs
ALXO ALX Oncology	$0.89 -8.7%	$1.74	$0.89 ▼ $2.66	$123.72M	0.47	1.06 million shs	2.57 million shs
AVXL Anavex Life Sciences	$1.49 +0.7%	$2.64	$1.44 ▼ $9.50	$138.12M	1.17	1.25 million shs	1.23 million shs
OTLK Oncobiologics	$0.47 -16.6%	$0.68	$0.16 ▼ $2.54	$114.47M	0.66	12.16 million shs	9.56 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	-0.36%	+2.42%	+5.56%	-4.51%	-41.82%
ALXO ALX Oncology	-22.25%	-11.75%	-49.51%	-51.74%	-47.05%
AVXL Anavex Life Sciences	-1.99%	-7.50%	-43.51%	-40.80%	-82.83%
OTLK Oncobiologics	-4.44%	-1.43%	-14.58%	-63.86%	-56.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	636.14% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	414.14% Upside
AVXL Anavex Life Sciences	2.40	Hold	$21.33	1,331.77% Upside
OTLK Oncobiologics	2.20	Hold	$5.20	1,005.91% Upside

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, AVXL, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	ALGS Aligos Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$4.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	14.90	N/A	N/A	$8.67 per share	0.60
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.10 per share	N/A
OTLK Oncobiologics	$1.35M	84.79	N/A	N/A	($0.60) per share	-0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
AVXL Anavex Life Sciences	-$46.38M	-$0.15	N/A	N/A	N/A	N/A	-11.43%	-10.72%	11/24/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	12/18/2026 (Estimated)

Latest ALGS, OTLK, AVXL, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	ALXO ALX Oncology	-$0.15	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	ALGS Aligos Therapeutics	-$2.44	N/A	N/A	N/A	$4.85 million	N/A
8/25/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.08	$0.08	+$0.16	$0.08	N/A	N/A
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
7/30/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
ALXO ALX Oncology	0.07	9.71	9.71
AVXL Anavex Life Sciences	N/A	15.62	15.62
OTLK Oncobiologics	N/A	0.81	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
ALXO ALX Oncology	97.97%
AVXL Anavex Life Sciences	31.55%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
ALXO ALX Oncology	12.40%
AVXL Anavex Life Sciences	11.00%
OTLK Oncobiologics	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	82	6.24 million	5.76 million	No Data
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
AVXL Anavex Life Sciences	34	92.70 million	82.50 million	Optionable
OTLK Oncobiologics	17	243.45 million	239.07 million	Optionable

ALGS, OTLK, AVXL, and ALXO Headlines

Recent News About These Companies

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

October 9, 2026 | globenewswire.com

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion

October 6, 2026 | globenewswire.com

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Hold" from Brokerages

October 4, 2026 | americanbankingnews.com

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Brokerages

October 4, 2026 | marketbeat.com

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

October 1, 2026 | globenewswire.com

Oncobiologics, Inc. (NASDAQ:OTLK) Short Interest Up 65.4% in August

September 17, 2026 | marketbeat.com

Brokers Offer Predictions for Oncobiologics FY2026 Earnings

September 17, 2026 | marketbeat.com

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 | globenewswire.com

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

September 10, 2026 | globenewswire.com

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

August 27, 2026 | globenewswire.com

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27, 2026 | globenewswire.com

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

August 17, 2026 | zacks.com

Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)

August 15, 2026 | defenseworld.netD

Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock

August 15, 2026 | insidertrades.com

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

August 14, 2026 | zacks.com

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

August 14, 2026 | globenewswire.com

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

August 14, 2026 | benzinga.com

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

August 12, 2026 | globenewswire.com

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

August 10, 2026 | zacks.com

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

August 6, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, AVXL, and ALXO Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$5.23 -0.28 (-5.08%)

Closing price 04:00 PM Eastern

Extended Trading

$5.32 +0.09 (+1.63%)

As of 07:50 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALX Oncology NASDAQ:ALXO

$0.89 -0.08 (-8.67%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.04 (+4.50%)

As of 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Anavex Life Sciences NASDAQ:AVXL

$1.49 +0.01 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.01 (+0.34%)

As of 07:30 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Oncobiologics NASDAQ:OTLK

$0.47 -0.09 (-16.60%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 +0.01 (+3.15%)

As of 07:59 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, AVXL, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALGS, OTLK, AVXL, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALGS, OTLK, AVXL, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, AVXL, and ALXO Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

ALX Oncology NASDAQ:ALXO

Anavex Life Sciences NASDAQ:AVXL

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALGS, OTLK, AVXL, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALGS, OTLK, AVXL, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALGS, OTLK, AVXL, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS, OTLK, AVXL, and ALXO Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

ALX Oncology NASDAQ:ALXO

Anavex Life Sciences NASDAQ:AVXL

Oncobiologics NASDAQ:OTLK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools